Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13 USD | +4.59% | -15.69% | 0.00% |
May. 14 | Kyverna Therapeutics Q1 Loss Narrows | MT |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Business Summary
Number of employees: 96
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Portia Serame
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Fred Cohen
BRD | Director/Board Member | 67 | 17-12-31 |
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Brian Kotzin
BRD | Director/Board Member | 74 | 19-07-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 43,115,244 | 38,489,732 ( 89.27 %) | 0 | 89.27 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 560M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+43.96% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- KYTX Stock
- Company Kyverna Therapeutics, Inc.